Drug candidates that enter the platform trial are selected by a group of expert ALS scientists and members of the Healey & AMG Center Therapy Evaluation Committee. Enrollment is now complete for the fourth investigational treatment (pridopidine) in the ongoing study.Learn More
Sean M. Healey & AMG Center for ALS
News & Events
Recent Media CoverageView All
BioPharma Dive spoke with Chief of Neurology Merit Cudkowicz, MD, MSc during their coverage of advances, setbacks and promising new research on ALS.
An abnormal version of tau, a protein associated with Alzheimer’s disease, may contribute to the progression of amyotrophic lateral sclerosis (ALS) by damaging mitochondria in neurons, according to a new study from Mass General Investigator Gahaleh Sadri-Vakili, PhD.
Make a Difference for the Healey Center
Join our quest to discover life-saving therapies for individuals who are affected by ALS. The key to our success is our dedication to collaboration. At the Sean M. Healey and AMG Center for ALS at Mass General, we partner with the best clinician-scientists, our patients and friends like you to turn laboratory successes into promising therapies.